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This paper reviews several monitoring studies where the short-term HPRT assay has been applied. The
original method uses autoradiography to detect 3H-thymidine incorporation in variant cells that have
undergone DNA synthesis; the bromodeoxyuridine modification employs this thymidine analog and fluores-
cence plus Giemsa staining. The studies discussed here were accomplished with either of these methods.
methods. Exposures analyzed include radiation and chemotherapy as medical treatments and accidental
exposures to radiation; these studies have been useful in the validation of the assay because radiation and
anticancer drugs are well-known mutagens. Other potential mutagens such as environmental arsenic and a
parasitic infection andpraziquantel, usedforitstreatment, have alsobeen monitoredforhprtlocus mutation.
An overview ofthe results obtained with different agents and routes ofexposure is presented here as well as
some methodological aspects for the optimization ofthe assay for monitoring studies.
Introduction
The HPRTT-lymphocytes assayisthemostwidelyused
genemutation assayforhumanmonitoringstudies (1).The
long-term cloning assay measures the frequency of
thioguanine-resistant (TGr) T-lymphocytes and simul-
taneously allows the recovery and further analysis of
individual clones to measure themutationfrequency(MF).
The exact nature of the hprt mutation can be defined by
Southern blotting and DNA sequencing (1).
The short-term assay can be done either by auto-
radiography to detect tritiated thymidine (3H-Tdr) incor-
poration in cells thathaveundergone DNAsynthesis (2) or
by the bromodeoxyuridine (BrdUrd) modification, which
uses this thymidine analog and fluorescence plus Giemsa
(FPG) staining (3). These short-term assays have been
proposed as useful forpopulation monitoringbecause they
are relatively inexpensive, simple, and available to any
cytogenetic laboratory.
The HPRT Short-Term Assay
Detailed methods have been described elsewhere (2,3).
Briefly, peripheral blood lymphocytes separated by Ficoll-
Hypaque centrifugation are cryopreserved at -70°C in
RPMI 1640 mediumwith 10% autologous plasma and 7.5%
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dimethyl sulfoxide at a cellular density of107 celVmL. The
cultures for thioguanine (TG) selection are set up after
thawing the cells at a density of 5 x 106 cells/mL in
RPMI-1640 with 20% autologous plasma, stimulated with
phytohemagglutinin and incubated at 37°C for 24 hr.
Twentymicroliters of3H-Tdr (6.7 Ci/mmole) or 200 1L of
BrdUrd (4 x 10-4 M final concentration) are added for
the last 16 hr of culture. Incubation is ended with 0.1 M
citricacid, and cultures arefLxedwithmethanol:acetic acid
(7:1.5).
Slides for microscopic evaluation are prepared and pro-
cessed for autoradiography or are stained by the FPG
method. Thelabelingindex(LI,) ofcontrolpreparations is
calculated as follows: LIC = no. of labeled nuclei/5000
evaluated nuclei. IntheTGculturepreparations, LIt = no.
of labeled nuclei (variants)/total number of nuclei
recovered from TG cultures. The variant frequency (VF)
index is then calculated as LIt/LI,.
Quantitative Measurements of Variant
Frequency in Human Somatic Cells
The backgrounds for normal adults determined by the
autoradiographic or the BrdUrd assay, using cryopre-
served cells, are listed in Table 1. These studies, whether
using 3H-Tdr or BrdUrd, show similar mean VF values
(5.9 x 10-6 and 4.82 x 10-6, respectively). Thesevalues
arecomparabletothemeanMFfoundinstudieswherethe
cloning assaywas used (5.25 x 10-6). Values reported by
several authors (1,3,5,8) show differences, and a distribu-
tion ofvariantfrequencies hasbeenfound. ConsideringallMONTERO ET AL.
ITable 1. Variant frequencies (3H-Tdr and BrdUrd methods): controls.
Mean frequency Range
Exposure lype of assay No. of samples (x 10-6) + SD (x 10-6) Reference
Control 3H-Tdr 18 7.12 + 7.16 0.50-22.3 (3)
Control :H-Tdr 82 8.70 + 6.10 1.00-28.9 (1)
Control 3H-Tdr 8 1.92 + 0.85 0.68- 3.24 (5)
Total average = 5.9
Control BrdUrd 2 4.31 + 1.68 (3)
Control BrdUrd 5 6.35 + 1.53 4.20- 8.40 (8)
Control BrdUrd 15 3.15 + 4.28 0.52-14.13 This paper
Total average = 4.82
Cloning 252 5.25 (,)a
aCalculated fromTable 1 from Albertini et al. (1).
the studies together, the range ofvalues is from 0.0 to 28.9 x 10-6. In each study, different means have been found, thus there is also a range ofmean
values from 1.92 X 10-6 to 8.7 x 10-6.
Significant increases of VFs have been reported in
cancer patients treated with chemotherapy or radio-
therapy (4-6) or in individuals exposed in radiation acci-
dents (Table 2) (7,8). These studies have been useful in
validating the assay. With respect to radiation, as with
other end points, data obtained on the VF values show a
clear-cut effect in the case of accidental exposures (7,8).
Patients receivinglocalized andfractionated radiotherapy
(4) also showed clear increases of VF, but smaller
increases than in the case of accidental exposure. The
range ofdata found in this study is 0.0-27.8 x 10-6. The
highestvalue corresponds to those in the range found for
healthy controls in other studies (Table 1), but since this
was a longitudinal study started before treatment and
followed every month, differences in VF could clearly be
observed because each individual served as his orher own
control.
In a study on patients receiving chemotherapy and/or
radiotherapy, a clear increase in the range of VFs was
found: from 0 to 135 x 10-6 in comparison to controls,
which showed a range of 0-16.5 x 10-6. Some of the
treated patients had aVF value greater than the highest
value ofcontrols, as expected since these drugs and radia-
tion are well-known mutagens and their effect should be
clearly detected; nevertheless, a high percentage of the
individualsexposed showedVFvaluesinthecontrol range
(more than 50%).
In the case of exposure to a single chemical, the well-
known cytostatic drug cyclophosphamide has been stud-
ied in a group ofworkers involved in its production and in
patientsundertreatmentformultiple sclerosis (5,9). Inthe
first case, a clearincrease inVF was foundin the exposed
workers (data are not included due to noncomparable VF
values because cells were not cryopreserved). In the study
ofmultiple sclerosis patients, five showed a clear increase
inVF after14 daysoftreatment, and only onedidnotshow
an increase (probably due to trimethoprim treatment).
Chronic exposure to arsenic in drinking water did not
show aneffect onthevariationfrequencyofhprtlocus (10).
In general, VF in the exposed group were higher than
those found in the low-exposure group (mean + SD: 5.03
X 10-6 + 2.99 2.48 x 10-6 + 2.2,respectively), butallthe
values are in the range found for the control, unexposed
group (from 0.52 x 10-6 to 14.13 x 10-6) (Fig. 1, Table 1
and 2). Statistically, no significant difference was found
among any ofthese groups.
Mean variant frequencies among neurocysticercotic
patients, exposed to several mutagenic treatments (anti-
convulsants, computerized axial tomography, anesthetics,
antibiotics, and anti-inflammatory drugs) show signifi-
Table 2. Variant frequencies (3H-Tdr and BrdUrd methods): exposed individuals.
Mean frequency
Exposure Type of assay No. ofsamples (x 10-6) ± SD Range Reference
Radiation accident
Cobalt-60 3H-Tdr 2 122.0 ± 5.9 18.6 -126.2 (11)
Cesium-137 BrdUrd 4 194.0 ± 147.0 36.0 -130.0 (8)
Cancer patients
Pretreatment 3H-Tdr 10 3.0 ± 1.7 0.0 - 6.1 (4)
Radiotherapy 3H-Tdr 9 12.6 + 8.7 2.5 - 23.8 (4)
Chemotherapy plus radiotherapy 3H-Tdr 35 24.00a 0.0 -135.0 (7)
Multiple sclerosis (MS)
Pretreatment 3H-Tdr 6 4.07 ± 3.1 0.83- 9.9 (5)
MS + cyclophosphamide 3H-Tdr 4 32.53 ± 13.97 11.6 - 40.3 (5)
LowAs BrdUrd 7 2.48 ± 2.19 0.68- 6.36 (11)
High As BrdUrd 7 5.03 ± 2.99 1.66- 9.65 (11)
Neurological patients BrdUrd 6 9.49 ± 6.25 3.33- 20.79 This paper
Neurocysticeroctic (NC)patients BrdUrd 22 14.48 ± 24.89 1.46-101.01 This paper
NC + praziquantel BrdUrd 12 17.55 ± 27.10 3.03-102.51 This paper
aDeviation could not be determined from the original paper.
bThese patients were exposed to several mutagenic agents before praziquantel treatment.
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FIGURE 1. Cumulative variant frequencies (VF) found in individuals
exposed to different agents. Controls are found among the lowest values
in the scale; exposed persons distribute widely.
cantly increased VF values in relation to healthy controls:
14.48 x 10 - 6and3.15 x 10 -6,respectively(Fig. 1,Tables 1
and 2). These patients did not statistically differ from an
appropriate control group, which consisted ofneurological
patients exposed to the same mutagenic treatments, but
who were not infected.
Seven of the 22 patients could be studied before and
after praziquantel treatment: 4 had a lower VF after
treatment, 2 did not show any significant difference, and 1
increased. Meanvaluebefore treatment was28.78 x 10 -6
and after treatment was 22.4 x 10-6; these values are
different from controls, but there is no significant dif-
ference between them (Fig. 2).
Some Methodological Aspects of
Monitoring Studies
An appropriate studydesign is fundamental. Forexample,
in the case ofthe radiotherapy study ofAmmenheuser et
al. (4), effects could be observed because sampling was
performed before, during, and after treatment, allowing
the observation of a dose-related response due to the
cumulative effect characteristic ofradiation. When study-
ingchemicals, this type ofdesign is difficult to accomplish;
in the best of the cases, patients are sampled only before
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FIGURE 2. Variantfrequency values in seven neurocysticercotic patients
before and after praziquantel treatment.
and after treatment, or a control group is compared to an
exposed group. When these protocols are used, overlap-
pingranges areusuallyfound, so thatmost ofthe exposed
individuals cannot be distinguished from normals.
Sampling time is another factor discussed by Ammen-
heuser et al. (4,5) when studying individuals exposed to
medical treatments. At least 15 days would be necessary
for the mutations produced by exposure to be manifested
in cells, and once treatments ended, there would be a
period during which mutation frequency increases could
bedetectedbeforethemutantcells areeliminatedfromthe
bodybyhomeostaticmechanisms, as suggestedfromtheir
studies (4,5).
But generalizations cannot be made because there are
exposures that apparently produce more persistent
damage as was observed with radiation accidents where
samples were taken 17months (7) and 24 months (8) after
the accident and still showed high VF values.
Interpretation of Results
Interpretation of effects is not an easy task due to the
variations in control values from healthy subjects, as
alreadystated. Controlsgenerallyaregrouped aroundthe
smallest values and when there is an exposure, these
values become less frequent. It has been proposed that
human population monitoring for mutagenicity is con-
cerned with group means, and in identifying individual
values that are above the range for normals (1). Nonethe-
less,variabilityraises several questions abouttherangeto
be considered normal, and if means could be used to
compare different groups, and which values should be
consideredpositive dueto exposure. Should a small shiftin
the distribution ofvalues ofexposed people be interpreted
as a risk for health, or should we expect no overlapping to
considerpositive aneffect? It shouldbeborneinmind that
ithas notbeen establishedwhich amountandwhatkind of
damage is hazardous for health.
Although there is an overlap of VF ranges between
controls and exposed groups, the way they distribute is
different, i.e., more elevated VFs are found in more indi-
viduals so that distributions are shifted toward higher
mean values (Fig. 1) when there is an exposure. It is
interesting to point out that the "outliers" with excep-
tionally high VFs may represent more susceptible indi-
viduals. This susceptibility could be due to pharmaco-
genetic differences (11,12) and should be investigated fur-
ther. In tryingtoidentifyriskgroups,we oftenforgetthat
individuals are the ones who suffer cancer and reproduc-
tive damage; the obvious question is if outliers are the
individuals prone to genetic health effects.
The need for studies of larger groups should be
stressed, but this can only be achieved by speeding up
microscopic analysis, which is time consuming. Computer
image analysis or cytofluorometry are viable solutions,
and in this respect it has recently been applied an immu-
nohistochemical antibromodeoxyuridine staining for
determination of 6-TGr T-lymphocytes, which has the
potential for automation (13).
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